Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Concurrent Gainers : 13 smallcap stocks gained for 5 straight sessions
25/10/2025
QSIF Equity Ex-Top 100 Long-Short Fund is open for subscription. 7 things to know
25/10/2025
Spandana Sphoorty raises Rs 250 crore, less than target
25/10/2025
Gold ETFs : After 27% surge in 3 months and sudden slide, what's next for investors ?
25/10/2025
Money-losing companies with colorful histories have pivoted to crypto
25/10/2025
Ashish Kacholia’s Rs 2,800-crore portfolio gets new gem that’s delivered 200% returns in 8 months
25/10/2025
